痴呆症的不断变化的治疗景观与利维体
Lorraine V Kaila1, Manabu Ikeda2, Janet Sultana3
1Edmond J Safra Program in Parkinson's Disease, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada; Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
The Lancet. Neurology
|November 15, 2025
概括
患有莱维体的痴呆症呈现出复杂的症状,影响认知,运动功能等. 目前的管理整合了症状治疗,越来越重视针对关键病理机制的疾病修饰疗法.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 老年病的医生 老年病的医生
背景情况:
- 患有莱维体的痴呆症 (DLB) 呈现出多方面的临床特征,影响认知,神经精神,运动,自主和睡眠功能.
- DLB对患者发病率,护理人员负担和医疗保健费用做出了重大贡献.
- 目前对DLB的症状治疗方法有限,需要综合管理策略.
研究的目的:
- 审查复杂的临床表现的痴呆症与勒维体.
- 讨论目前和新兴的DLB治疗策略.
- 突出DLB研究中转向疾病修饰疗法的转变.
主要方法:
- 临床表现和莱维体痴呆症管理的文献综述.
- 分析当前的药理和非药理干预措施.
- 对DLB的新兴治疗目标和正在进行的临床试验的审查.
主要成果:
- 患有勒维体的痴呆症在多个领域呈现出各种不同的症状.
- 建议将药理和非药理干预相结合的综合方法用于症状管理.
- 新的治疗点,包括α-synuclein,神经炎症和β-粉样蛋白,正在研究疾病修饰.
结论:
- 一种全面的,多方面的方法对于管理患有勒维体的痴呆症至关重要.
- 该领域正在向疾病修饰疗法推进,为患者提供新的希望.
- 了解常见的共同病理,如阿尔茨海默病,对于有效的DLB治疗至关重要.
相关概念视频
Alzheimer's Disease: Treatment
782
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782
Dementia
503
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
503
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Treatment
954
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
954
Drug Therapy
236
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
236


